8-K: Rapport Therapeutics Announces Positive Phase 2 Bipolar Mania Trial Results

Rapport Therapeutics reports positive topline results from its Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with a well-tolerated safety profile.

Summary

• Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of acute mania associated with bipolar I disorder.
• The trial met its primary endpoint, showing a statistically significant 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale (YMRS) total score at Week 3 (p=0.045).
• RAP-219 also met its pre-specified secondary endpoint, demonstrating a statistically significant improvement in mania severity as measured by the Clinical Global Impression-Bipolar Version (CGI-BP) mania severity scale (0.4 points; p=0.024).
• The drug was well-tolerated, with all treatment-emergent adverse events (TEAEs) being mild or moderate, and no serious adverse events (SAEs) observed during the three-week treatment period.
• These results establish clinical proof-of-concept for RAP-219, supporting progression to Phase 3 trials expected to begin in the second half of 2027.
• The company plans to meet with the FDA in Q1 2027 to discuss the Phase 2 data and registrational trial design.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with the Phase 2 trial meeting its primary and secondary endpoints and demonstrating a favorable safety profile, paving the way for Phase 3 trials.

Positives

• The Phase 2 trial met its primary endpoint, demonstrating a statistically significant placebo-adjusted improvement in YMRS total score (3.1 points, p=0.045).
• The trial also met its secondary endpoint, showing a statistically significant improvement in CGI-BP mania severity score (0.4 points, p=0.024).
• RAP-219 was well-tolerated, with a similar incidence of TEAEs to placebo (51.6% vs 52.8%).
• All TEAEs were mild or moderate, and no serious adverse events (SAEs) were reported during the treatment period.
• The incidence of TEAEs leading to discontinuation was low (3.2% for RAP-219 vs 0.8% for placebo).
• Adverse effects commonly associated with current bipolar mania medications, such as orthostatic hypotension, akathisia, and extrapyramidal symptoms, were not reported.
• Somnolence was reported less often with RAP-219 (0.8%) than placebo (3.1%).
• The company has sufficient cash reserves ($436.1 million as of June 30, 2026) to fund operations into the second half of 2029.

Negatives

• A higher percentage of patients on RAP-219 discontinued treatment due to a TEAE compared to placebo (3.2% vs 0.8%).
• Withdrawal of consent was a significant reason for discontinuation in the RAP-219 group (16.7% vs 4.7% for placebo), with reasons including wanting to leave the inpatient unit.
• Nausea was the only TEAE reported approximately twice as often in the RAP-219 group compared to placebo (5.6% vs 1.6%).
• Agitation was the most common TEAE on RAP-219 (16.7%), though generally mild/moderate and considered unrelated in over 80% of cases.

Risks

• Risks related to the company's research and development activities.
• Uncertainties relating to preclinical and clinical development activities.
• Dependence on third parties for clinical trials, manufacturing, and commercialization.
• Ability to attract, integrate, and retain key personnel.
• Need for substantial additional funds to complete development and commercialization.
• Regulatory developments and approval processes.
• Establishing and maintaining intellectual property protections.
• The competitive landscape for product candidates.

Future Outlook

The company anticipates initiating two Phase 3 trials for RAP-219 in acute bipolar mania in the second half of 2027, following an End-of-Phase 2 meeting with the FDA in the first quarter of 2027. Additional data from the Phase 2 trial will be presented at a future medical meeting. Other upcoming milestones include data from Phase 3 trials in focal onset seizures and primary generalized tonic-clonic seizures, Phase 1 data for a long-acting injectable formulation of RAP-219, and preliminary results for RAP-641.

Management Comments

• "For people with bipolar disorder, the challenge isnt just finding a treatment thats efficacious. Its finding one they can tolerate and stay on. Side effects drive discontinuation, and discontinuation drives relapse. RAP-219 has the potential to break that cycle with the first new mechanism of action for bipolar mania in decades."
• "Together with our positive Phase 2 focal epilepsy data, these results strengthen RAP-219s profile across each indication we are pursuing and show it delivering on its potential as a pipeline-in-a-product with two indications that both represent multibillion dollar market opportunities."
• "In this proof-of-concept study, RAP-219 demonstrated statistically significant improvement across measures of mania symptoms as well as a favorable tolerability profile, said Jeffrey Sevigny, M.D., chief medical officer of Rapport. This is important because tolerability issues lead many patients to discontinue their therapies."
• "Importantly, clinical benefit was seen consistently across all measures, with the greatest improvements in symptoms that tend to drive hospitalization for acute mania patients. What is encouraging about the tolerability profile is what was not seen on RAP-219--the somnolence, akathisia, and extrapyramidal symptoms that often cause patients to discontinue treatment."

Industry Context

StockSavvy.ai notes that the announcement positions Rapport Therapeutics to potentially offer a novel treatment option in the bipolar mania market, which has seen limited new mechanisms of action in decades. The positive Phase 2 results, particularly the favorable tolerability profile, could differentiate RAP-219 from existing therapies that often suffer from adherence issues due to side effects.

Comparison to Industry Standards

• The primary endpoint improvement of 3.1 points (placebo-adjusted) on the YMRS is a key metric in bipolar mania trials. While direct comparisons are complex due to trial variations, this result is considered clinically meaningful and supports the drug's efficacy.
• The low incidence of serious adverse events (SAEs) and the absence of commonly associated side effects like akathisia and extrapyramidal symptoms align with the industry's drive for safer neurological treatments.
• The company's cash runway extending into the second half of 2029 is a positive indicator of financial stability, crucial for navigating the lengthy and expensive Phase 3 development process common in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Positive trial results and clear development path are likely to be viewed favorably, potentially impacting stock price.
• Patients with Bipolar Mania: Potential for a new treatment option with a differentiated mechanism and favorable tolerability profile, which could improve adherence and outcomes.
• Healthcare Providers: May see a new therapeutic option to manage acute manic episodes, especially for patients who struggle with current treatments.
• Employees: Continued progress in clinical development can boost morale and reinforce the company's mission.

Next Steps

• Meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 to discuss Phase 2 data and registrational trial design for RAP-219 in bipolar mania.
• Initiate two Phase 3 trials of RAP-219 in acute bipolar mania in the second half of 2027.
• Present additional data from the Phase 2 trial at a future medical meeting.
• Enroll patients in FOCUS 1 and FOCUS 2 pivotal Phase 3 trials for focal onset seizures.
• Present initial data from the long-term open-label extension of the Phase 2a trial in focal onset seizures in Q4 2026.
• Begin Phase 3 trial for primary generalized tonic-clonic seizures in the first half of 2027.
• Present Phase 1 pharmacokinetic data for a long-acting injectable formulation of RAP-219 in Q3 2027.
• Present Phase 1 preliminary results for RAP-641 in the second half of 2027.

Key Dates

Recommendation

The positive Phase 2 results are encouraging and de-risk the program for Phase 3. However, the company is still several years away from potential market approval, and significant execution risk remains in the upcoming Phase 3 trials and regulatory processes. The current cash runway is adequate, but future capital needs for late-stage development and commercialization will need to be monitored. Therefore, a 'hold' recommendation is appropriate, awaiting further data from Phase 3 trials and regulatory interactions.

Keywords

bipolar mania, RAP-219, Phase 2 trial, clinical trial results, psychiatric disorders, neurological disorders, biotechnology, drug development